← 返回

新辅助化疗调节高级别浆液性癌中的肥大细胞表型和免疫浸润

英文原题:Neoadjuvant chemotherapy modulates mast cell phenotypes and immune infiltration in high-grade serous carcinoma.

查看英文原题

Neoadjuvant chemotherapy modulates mast cell phenotypes and immune infiltration in high-grade serous carcinoma.

PubMed 2025/11/01(内容时间) Gynecol Oncol Q1 · IF 4.5(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

成功的 NACT 与 CD52+ KIT+肥大细胞减少及 JUN+/TNFRSF12A+亚群增加相关。KIT 表达肥大细胞浸润增加可作为 HGSC 患者接受 NACT 后的预后生物标志物,并代表一个潜在的新型治疗靶点,用以增强 NACT 疗效。

研究思路结论见上方概要

新辅助化疗(NACT)对高级别浆液性癌(HGSC)免疫微环境的影响尚不明确。本研究旨在探讨HGSC组织在NACT前后免疫浸润的差异模式及其临床意义。

使用我们的内部RNA测序数据(包括8例NACT前和7例NACT后肿瘤样本)、三个GEO数据集(GSE181597、GSE201600、GSE227666)以及对73对NACT前后样本的免疫组织化学分析,分析了HGSC组织中NACT前后的免疫浸润模式。使用化疗反应评分(CRS)评估对NACT的反应,将患者分为应答者(CRS = 3)和无应答者(CRS = 1/2)。利用单细胞RNA测序数据(GSE165897)进行Scissor和拟时序分析,以研究肥大细胞表型相关细胞群体和发育轨迹。

NACT 引发了免疫细胞浸润的动态改变,尤其以 CD8+ T 细胞和肥大细胞浸润增加为特征,这一结果得到了免疫组织化学的证实。NACT 后,KIT 表达显著升高,尤其在应答者中,而在 NACT 前,应答者与非应答者之间未检测到显著差异。KIT 表达升高与不良预后相关。NACT 后,肥大细胞从 CD52 + KIT+ 向 JUN+/TNFRSF12A+ 亚群转变。

展开英文摘要原文

The influence of neoadjuvant chemotherapy (NACT) on the immune landscape of high-grade serous carcinoma (HGSC) remains inadequately understood. This study aims to investigate the differential patterns of immune infiltration in HGSC tissues before and after NACT, as well as their clinical significance.

Immune infiltration patterns in HGSC tissues pre- and post-NACT were analyzed using our in-house RNA sequencing data (comprising 8 pre-NACT and 7 post-NACT tumor samples), three GEO datasets (GSE181597, GSE201600, GSE227666), and immunohistochemistry on 73 paired pre- and post-NACT samples. The response to NACT was evaluated using the Chemotherapy response score (CRS), categorizing patients as responders (CRS = 3) and non-responders (CRS = 1/2). Scissor and pseudotime analyses were conducted to investigate mast cell phenotype-associated cell populations and developmental trajectories utilizing single-cell RNA sequencing data (GSE165897).

NACT prompted dynamic alterations in immune cell infiltration, notably characterized by an increase in CD8+ T cells and mast cell infiltration, which were corroborated by immunohistochemistry. Following NACT, there was a notable increase in KIT expression, particularly among responders, whereas no significant difference was detected between responders and non-responders prior to NACT. Elevated KIT expression was linked to a poor prognosis. There was a transition from CD52 + KIT+ mast cells to JUN+/TNFRSF12A+ subsets post-NACT.

Successful NACT was associated with a reduction in CD52 + KIT+ mast cells and an increase in the JUN+/TNFRSF12A+ subpopulation. The increased infiltration of KIT-expressing mast cells may serve as a prognostic biomarker for HGSC following NACT and represent a potential novel therapeutic target to enhance NACT efficacy.

论文信息

作者
Fan Y、Wang Q、Deng H、Liu Y、Zhang H
第一作者单位
Department of Gynecology, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China.China
通讯作者单位
Department of Gynecology, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China. Electronic address: zhanghui@hebmu.edu.cn.China
文献类型
非美国政府资助研究
期刊
Gynecologic oncology2025 Dec
原文标识
PubMed 41176887 · DOI 10.1016/j.ygyno.2025.10.014